Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
Phase 1
Completed
- Conditions
- Insulin ResistanceObesity
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT00398619
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT00393120
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
Phase 2
Terminated
- Conditions
- Human Immunodeficiency VirusHIV Infections
- Interventions
- First Posted Date
- 2006-03-09
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT00300573
© Copyright 2025. All Rights Reserved by MedPath